Last 12 months
Inside the activity.
1 purchase rows · 0 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 1 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 27, 2020 Filed Nov 30, 2020 22:11 UTC |
Guerin Mark PatrickChief Financial Officer
|
PurchaseCommon Stock | 4,614 | $0.26 | $1,199.64 |
DisclosureSEC source: 0001179110-20-011470 · edgar.xml · nonDerivative · entry 2 Guerin Mark Patrick · CIK 0001607714 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,213 Read SEC document |
| November 25, 2020 Filed Nov 30, 2020 22:14 UTC |
Shoemaker Mary TeresaDirector
|
PurchaseCommon Stock | 37,735 | $0.27 | $9,999.78 |
DisclosureSEC source: 0001179110-20-011471 · edgar.xml · nonDerivative · entry 1 Shoemaker Mary Teresa · CIK 0001813552 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,735 F1 · balance_after: Includes 37,735 shares held by the M. Teresa Shoemaker Revocable Trust U/A DTD 08/01/2000, of which the reporting person is a trustee. Read SEC document |
| November 25, 2020 Filed Nov 30, 2020 22:11 UTC |
Guerin Mark PatrickChief Financial Officer
|
PurchaseCommon Stock | 16,755 | $0.26 | $4,356.30 |
DisclosureSEC source: 0001179110-20-011470 · edgar.xml · nonDerivative · entry 1 Guerin Mark Patrick · CIK 0001607714 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,599 Read SEC document |
| November 25, 2020 Filed Nov 30, 2020 22:09 UTC |
OLER ABRAHAM N.SVP Corp Dev & Gen Counsel
|
PurchaseCommon Stock | 20,000 | $0.26 | $5,120.00 |
DisclosureSEC source: 0001179110-20-011469 · edgar.xml · nonDerivative · entry 1 OLER ABRAHAM N. · CIK 0001557372 · SVP Corp Dev & Gen Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,000 F1 · balance_after: Includes 35,000 shares held by the Abraham Oler Living Trust U/T/A DTD 07/27/2012, of which the reporting person is a trustee. Read SEC document |
| November 25, 2020 Filed Nov 30, 2020 22:08 UTC |
Fruchtman Steven MDirector · President, Chief Executive Off
|
PurchaseCommon Stock | 40,000 | $0.26 | $10,360.00 |
DisclosureSEC source: 0001179110-20-011468 · edgar.xml · nonDerivative · entry 1 Fruchtman Steven M · CIK 0001631251 · Director · President, Chief Executive Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 216,226 Read SEC document |
| November 24, 2020 Filed Nov 27, 2020 18:34 UTC |
MARINO JAMES JDirector
|
PurchaseCommon Stock | 38,774 | $0.26 | $10,003.69 |
DisclosureSEC source: 0001179110-20-011442 · edgar.xml · nonDerivative · entry 1 MARINO JAMES J · CIK 0001198578 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 205,716 Read SEC document |
| August 27, 2020 Filed Aug 31, 2020 20:49 UTC |
Reddy E PremkumarDirector
|
SaleCommon Stock | 527,863 | $0.27 | $143,948.24 |
DisclosureSEC source: 0001179110-20-009439 · edgar.xml · nonDerivative · entry 1 Reddy E Premkumar · CIK 0001580071 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,683 Read SEC document |
| August 27, 2020 Filed Aug 31, 2020 20:42 UTC |
Hoffman Michael BDirector
|
SaleCommon Stock | 1,876 | $0.27 | $510.08 |
DisclosureSEC source: 0001179110-20-009437 · edgar.xml · nonDerivative · entry 2 Hoffman Michael B · CIK 0001290208 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| August 27, 2020 Filed Aug 31, 2020 20:42 UTC |
Hoffman Michael BDirector
|
SaleCommon Stock | 182,492 | $0.27 | $49,619.57 |
DisclosureSEC source: 0001179110-20-009437 · edgar.xml · nonDerivative · entry 1 Hoffman Michael B · CIK 0001290208 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By the Michael and Jane Hoffman 2013 Descendants Trust Disclosed balance after: 21,919 F1 · ownership.nature: These shares are held for the benefit of the reporting person's descendants. The reporting person's spouse is a trustee of the trust. Read SEC document |
| July 09, 2020 Filed Jul 10, 2020 21:51 UTC |
OLER ABRAHAM N.SVP Corp Dev & Gen Counsel
|
GrantStock Appreciation Right · Derivative | 375,600 | $0.00 Strike: $0.56 | $0.00 |
DisclosureSEC source: 0001179110-20-008213 · edgar.xml · derivative · entry 1 OLER ABRAHAM N. · CIK 0001557372 · SVP Corp Dev & Gen Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 375,600 Underlying: Common Stock · 375,600 shares Expires 2030-07-09 F1 · derivative.exercise_date: These stock appreciation rights vest over three years, one-third on the first anniversary of the date of grant and thereafter in 24 equal monthly installments over the following two years. Read SEC document |
| July 09, 2020 Filed Jul 10, 2020 21:48 UTC |
Guerin Mark PatrickChief Financial Officer
|
GrantStock Appreciation Right · Derivative | 543,000 | $0.00 Strike: $0.56 | $0.00 |
DisclosureSEC source: 0001179110-20-008212 · edgar.xml · derivative · entry 1 Guerin Mark Patrick · CIK 0001607714 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 543,000 Underlying: Common Stock · 543,000 shares Expires 2030-07-09 F1 · derivative.exercise_date: These stock appreciation rights vest over three years, one-third on the first anniversary of the date of grant and thereafter in 24 equal monthly installments over the following two years. Read SEC document |
| July 09, 2020 Filed Jul 10, 2020 21:43 UTC |
Maniar ManojSVP - Product Development
|
GrantStock Appreciation Right · Derivative | 418,600 | $0.00 Strike: $0.56 | $0.00 |
DisclosureSEC source: 0001179110-20-008210 · edgar.xml · derivative · entry 1 Maniar Manoj · CIK 0001642906 · SVP - Product Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 418,600 Underlying: Common Stock · 418,600 shares Expires 2030-07-09 F1 · derivative.exercise_date: These stock appreciation rights vest over three years, one-third on the first anniversary of the date of grant and thereafter in 24 equal monthly installments over the following two years. Read SEC document |
| July 09, 2020 Filed Jul 10, 2020 21:46 UTC |
Woodman Richard CharlesChief Medical Officer
|
GrantStock Appreciation Right · Derivative | 396,000 | $0.00 Strike: $0.56 | $0.00 |
DisclosureSEC source: 0001179110-20-008211 · edgar.xml · derivative · entry 1 Woodman Richard Charles · CIK 0001758427 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 396,000 Underlying: Common Stock · 396,000 shares Expires 2030-07-09 F1 · derivative.exercise_date: These stock appreciation rights vest over three years, one-third on the first anniversary of the date of grant and thereafter in 24 equal monthly installments over the following two years. Read SEC document |
| July 09, 2020 Filed Jul 10, 2020 21:42 UTC |
Shoemaker Mary TeresaDirector
|
GrantStock Appreciation Right · Derivative | 125,000 | $0.00 Strike: $0.56 | $0.00 |
DisclosureSEC source: 0001179110-20-008209 · edgar.xml · derivative · entry 1 Shoemaker Mary Teresa · CIK 0001813552 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2030-07-09 F1 · derivative.exercise_date: These stock appreciation rights vest 100% on the first anniversary of the grant date. Read SEC document |
| July 09, 2020 Filed Jul 10, 2020 21:41 UTC |
Fruchtman Steven MDirector · President, Chief Executive Off
|
GrantStock Appreciation Right · Derivative | 1,273,800 | $0.00 Strike: $0.56 | $0.00 |
DisclosureSEC source: 0001179110-20-008208 · edgar.xml · derivative · entry 1 Fruchtman Steven M · CIK 0001631251 · Director · President, Chief Executive Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,273,800 Underlying: Common Stock · 1,273,800 shares Expires 2030-07-09 F1 · derivative.exercise_date: These stock appreciation rights vest over three years, one-third on the first anniversary of the date of grant and thereafter in 24 equal monthly installments over the following two years. Read SEC document |
| July 09, 2020 Filed Jul 10, 2020 21:36 UTC |
STOVER JACK EDirector
|
GrantStock Appreciation Right · Derivative | 125,000 | $0.00 Strike: $0.56 | $0.00 |
DisclosureSEC source: 0001179110-20-008207 · edgar.xml · derivative · entry 1 STOVER JACK E · CIK 0001203603 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2030-07-09 F1 · derivative.exercise_date: These stock appreciation rights vest 100% on the first anniversary of the grant date. Read SEC document |
| July 09, 2020 Filed Jul 10, 2020 21:33 UTC |
Reddy E PremkumarDirector
|
GrantStock Appreciation Right · Derivative | 125,000 | $0.00 Strike: $0.56 | $0.00 |
DisclosureSEC source: 0001179110-20-008202 · edgar.xml · derivative · entry 1 Reddy E Premkumar · CIK 0001580071 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2030-07-09 F1 · derivative.exercise_date: These stock appreciation rights vest 100% on the first anniversary of the grant date. Read SEC document |
| July 09, 2020 Filed Jul 10, 2020 21:32 UTC |
MEHTA VIRENDirector
|
GrantStock Appreciation Right · Derivative | 125,000 | $0.00 Strike: $0.56 | $0.00 |
DisclosureSEC source: 0001179110-20-008198 · edgar.xml · derivative · entry 1 MEHTA VIREN · CIK 0001238969 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2030-07-09 F1 · derivative.exercise_date: These stock appreciation rights vest 100% on the first anniversary of the grant date. Read SEC document |
| July 09, 2020 Filed Jul 10, 2020 21:30 UTC |
MARINO JAMES JDirector
|
GrantStock Appreciation Right · Derivative | 125,000 | $0.00 Strike: $0.56 | $0.00 |
DisclosureSEC source: 0001179110-20-008195 · edgar.xml · derivative · entry 1 MARINO JAMES J · CIK 0001198578 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2030-07-09 F1 · derivative.exercise_date: These stock appreciation rights vest 100% on the first anniversary of the grant date. Read SEC document |
| July 09, 2020 Filed Jul 10, 2020 21:29 UTC |
Hoffman Michael BDirector
|
GrantStock Appreciation Right · Derivative | 125,000 | $0.00 Strike: $0.56 | $0.00 |
DisclosureSEC source: 0001179110-20-008193 · edgar.xml · derivative · entry 1 Hoffman Michael B · CIK 0001290208 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2030-07-09 F1 · derivative.exercise_date: These stock appreciation rights vest 100% on the first anniversary of the grant date. Read SEC document |
| July 09, 2020 Filed Jul 10, 2020 21:28 UTC |
GROOPMAN JEROMEDirector
|
GrantStock Appreciation Right · Derivative | 125,000 | $0.00 Strike: $0.56 | $0.00 |
DisclosureSEC source: 0001179110-20-008191 · edgar.xml · derivative · entry 1 GROOPMAN JEROME · CIK 0001218853 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2030-07-09 F1 · derivative.exercise_date: These stock appreciation rights vest 100% on the first anniversary of the grant date. Read SEC document |
| May 19, 2020 Filed May 20, 2020 13:19 UTC |
OLER ABRAHAM N.SVP Corp Dev & Gen Counsel
|
PurchaseCommon Stock | 15,000 | $0.37 | $5,550.00 |
DisclosureSEC source: 0001179110-20-006359 · edgar.xml · nonDerivative · entry 1 OLER ABRAHAM N. · CIK 0001557372 · SVP Corp Dev & Gen Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Read SEC document |
| May 19, 2020 Filed May 20, 2020 13:09 UTC |
Guerin Mark PatrickChief Financial Officer
|
PurchaseCommon Stock | 21,000 | $0.36 | $7,560.00 |
DisclosureSEC source: 0001179110-20-006358 · edgar.xml · nonDerivative · entry 1 Guerin Mark Patrick · CIK 0001607714 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,844 Read SEC document |
| May 19, 2020 Filed May 20, 2020 13:07 UTC |
Fruchtman Steven MDirector · President, Chief Executive Off
|
PurchaseCommon Stock | 26,800 | $0.37 | $9,857.04 |
DisclosureSEC source: 0001179110-20-006357 · edgar.xml · nonDerivative · entry 1 Fruchtman Steven M · CIK 0001631251 · Director · President, Chief Executive Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 176,226 Read SEC document |
| May 19, 2020 Filed May 21, 2020 21:10 UTC |
GROOPMAN JEROMEDirector
|
PurchaseCommon Stock | 10,000 | $0.36 | $3,626.00 |
DisclosureSEC source: 0001179110-20-006452 · edgar.xml · nonDerivative · entry 1 GROOPMAN JEROME · CIK 0001218853 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,001 Read SEC document |
| December 20, 2019 Filed Dec 26, 2019 14:11 UTC |
Woodman Richard CharlesChief Medical Officer
|
GrantStock Option (right to purchase) · Derivative | 80,000 | $0.00 Strike: $0.31 | $0.00 |
DisclosureSEC source: 0001179110-19-013141 · edgar.xml · derivative · entry 1 Woodman Richard Charles · CIK 0001758427 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2029-12-20 F1 · derivative.exercise_date: These options vest over three years, one-third on the first anniversary of the date of grant and thereafter in 24 equal monthly installments over the following two years. Read SEC document |
| December 20, 2019 Filed Dec 26, 2019 14:08 UTC |
OLER ABRAHAM N.VP Corp Dev & Gen Counsel
|
GrantStock Option (right to purchase) · Derivative | 60,000 | $0.00 Strike: $0.31 | $0.00 |
DisclosureSEC source: 0001179110-19-013140 · edgar.xml · derivative · entry 1 OLER ABRAHAM N. · CIK 0001557372 · VP Corp Dev & Gen Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2029-12-20 F1 · derivative.exercise_date: These options vest over three years, one-third on the first anniversary of the date of grant and thereafter in 24 equal monthly installments over the following two years. Read SEC document |
| December 20, 2019 Filed Dec 26, 2019 14:07 UTC |
Fruchtman Steven MDirector · President, Chief Executive Off
|
GrantStock Option (right to purchase) · Derivative | 200,000 | $0.00 Strike: $0.31 | $0.00 |
DisclosureSEC source: 0001179110-19-013139 · edgar.xml · derivative · entry 1 Fruchtman Steven M · CIK 0001631251 · Director · President, Chief Executive Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2029-12-20 F1 · derivative.exercise_date: These options vest over three years, one-third on the first anniversary of the date of grant and thereafter in 24 equal monthly installments over the following two years. Read SEC document |
| December 20, 2019 Filed Dec 26, 2019 14:06 UTC |
Guerin Mark PatrickChief Financial Officer
|
GrantStock Option (right to purchase) · Derivative | 65,000 | $0.00 Strike: $0.31 | $0.00 |
DisclosureSEC source: 0001179110-19-013138 · edgar.xml · derivative · entry 1 Guerin Mark Patrick · CIK 0001607714 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2029-12-20 F1 · derivative.exercise_date: These options vest over three years, one-third on the first anniversary of the date of grant and thereafter in 24 equal monthly installments over the following two years. Read SEC document |
| December 20, 2019 Filed Dec 26, 2019 14:05 UTC |
Maniar ManojSVP - Product Development
|
GrantStock Option (right to purchase) · Derivative | 43,000 | $0.00 Strike: $0.31 | $0.00 |
DisclosureSEC source: 0001179110-19-013137 · edgar.xml · derivative · entry 1 Maniar Manoj · CIK 0001642906 · SVP - Product Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,000 Underlying: Common Stock · 43,000 shares Expires 2029-12-20 F1 · derivative.exercise_date: These options vest over three years, one-third on the first anniversary of the date of grant and thereafter in 24 equal monthly installments over the following two years. Read SEC document |
| November 25, 2019 Filed Nov 26, 2019 12:53 UTC |
MARINO JAMES JDirector
|
PurchaseWarrant (right to purchase) · Derivative | 150,000 | Not disclosed Strike: $0.20 | Not disclosed |
DisclosureSEC source: 0001179110-19-012058 · edgar.xml · derivative · entry 2 MARINO JAMES J · CIK 0001198578 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2024-11-25 F1 · price: The common stock and warrants were acquired in a public offering, by Onconova Therapeutics, Inc, of units which included one share of common stock and one warrant. The public offering price for each unit was $0.20. Read SEC document |
| November 25, 2019 Filed Nov 26, 2019 12:53 UTC |
MARINO JAMES JDirector
|
PurchaseCommon Stock | 150,000 | $0.20 | $30,000.00 |
DisclosureSEC source: 0001179110-19-012058 · edgar.xml · nonDerivative · entry 1 MARINO JAMES J · CIK 0001198578 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,942 F1 · price: The common stock and warrants were acquired in a public offering, by Onconova Therapeutics, Inc, of units which included one share of common stock and one warrant. The public offering price for each unit was $0.20. Read SEC document |
| November 25, 2019 Filed Nov 26, 2019 12:57 UTC |
Reddy E PremkumarDirector
|
PurchaseWarrant (right to purchase) · Derivative | 500,000 | Not disclosed Strike: $0.20 | Not disclosed |
DisclosureSEC source: 0001179110-19-012059 · edgar.xml · derivative · entry 2 Reddy E Premkumar · CIK 0001580071 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Underlying: Common stock · 500,000 shares Expires 2024-11-25 F1 · price: The common stock and warrants were acquired in a public offering, by Onconova Therapeutics, Inc, of units which included one share of common stock and one warrant. The public offering price for each unit was $0.20. Read SEC document |
| November 25, 2019 Filed Nov 26, 2019 12:57 UTC |
Reddy E PremkumarDirector
|
PurchaseCommon Stock | 500,000 | $0.20 | $100,000.00 |
DisclosureSEC source: 0001179110-19-012059 · edgar.xml · nonDerivative · entry 1 Reddy E Premkumar · CIK 0001580071 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 544,546 F1 · price: The common stock and warrants were acquired in a public offering, by Onconova Therapeutics, Inc, of units which included one share of common stock and one warrant. The public offering price for each unit was $0.20. Read SEC document |
| November 25, 2019 Filed Nov 26, 2019 12:46 UTC |
OLER ABRAHAM N.VP Corp Dev & Gen Counsel
|
PurchaseWarrant (right to purchase) · Derivative | 75,000 | Not disclosed Strike: $0.20 | Not disclosed |
DisclosureSEC source: 0001179110-19-012054 · edgar.xml · derivative · entry 2 OLER ABRAHAM N. · CIK 0001557372 · VP Corp Dev & Gen Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2024-11-25 F1 · price: The common stock and warrants were acquired in a public offering, by Onconova Therapeutics, Inc, of units which included one share of common stock and one warrant. The public offering price for each unit was $0.20. Read SEC document |
| November 25, 2019 Filed Nov 26, 2019 12:46 UTC |
OLER ABRAHAM N.VP Corp Dev & Gen Counsel
|
PurchaseCommon Stock | 75,000 | $0.20 | $15,000.00 |
DisclosureSEC source: 0001179110-19-012054 · edgar.xml · nonDerivative · entry 1 OLER ABRAHAM N. · CIK 0001557372 · VP Corp Dev & Gen Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 F1 · price: The common stock and warrants were acquired in a public offering, by Onconova Therapeutics, Inc, of units which included one share of common stock and one warrant. The public offering price for each unit was $0.20. Read SEC document |
| November 25, 2019 Filed Nov 26, 2019 12:51 UTC |
Fruchtman Steven MDirector · President, Chief Executive Off
|
PurchaseWarrant (right to purchase) · Derivative | 149,000 | Not disclosed Strike: $0.20 | Not disclosed |
DisclosureSEC source: 0001179110-19-012057 · edgar.xml · derivative · entry 2 Fruchtman Steven M · CIK 0001631251 · Director · President, Chief Executive Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,000 Underlying: Common Stock · 149,000 shares Expires 2024-11-25 F1 · price: The common stock and warrants were acquired in a public offering, by Onconova Therapeutics, Inc, of units which included one share of common stock and one warrant. The public offering price for each unit was $0.20. Read SEC document |
| November 25, 2019 Filed Nov 26, 2019 12:51 UTC |
Fruchtman Steven MDirector · President, Chief Executive Off
|
PurchaseCommon Stock | 149,000 | $0.20 | $29,800.00 |
DisclosureSEC source: 0001179110-19-012057 · edgar.xml · nonDerivative · entry 1 Fruchtman Steven M · CIK 0001631251 · Director · President, Chief Executive Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,426 F1 · price: The common stock and warrants were acquired in a public offering, by Onconova Therapeutics, Inc, of units which included one share of common stock and one warrant. The public offering price for each unit was $0.20. Read SEC document |
| November 25, 2019 Filed Nov 26, 2019 12:50 UTC |
Guerin Mark PatrickChief Financial Officer
|
PurchaseWarrant (right to purchase) · Derivative | 87,500 | Not disclosed Strike: $0.20 | Not disclosed |
DisclosureSEC source: 0001179110-19-012056 · edgar.xml · derivative · entry 2 Guerin Mark Patrick · CIK 0001607714 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,500 Underlying: Common Stock · 87,500 shares Expires 2024-11-25 F1 · price: The common stock and warrants were acquired in a public offering, by Onconova Therapeutics, Inc, of units which included one share of common stock and one warrant. The public offering price for each unit was $0.20. Read SEC document |
| November 25, 2019 Filed Nov 26, 2019 12:50 UTC |
Guerin Mark PatrickChief Financial Officer
|
PurchaseCommon Stock | 87,500 | $0.20 | $17,500.00 |
DisclosureSEC source: 0001179110-19-012056 · edgar.xml · nonDerivative · entry 1 Guerin Mark Patrick · CIK 0001607714 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,844 F1 · price: The common stock and warrants were acquired in a public offering, by Onconova Therapeutics, Inc, of units which included one share of common stock and one warrant. The public offering price for each unit was $0.20. Read SEC document |
| November 25, 2019 Filed Nov 27, 2019 13:33 UTC |
MEHTA VIRENDirector
|
PurchaseWarrant (right to purchase) · Derivative | 250,000 | Not disclosed Strike: $0.20 | Not disclosed |
DisclosureSEC source: 0001179110-19-012105 · edgar.xml · derivative · entry 4 MEHTA VIREN · CIK 0001238969 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2024-11-25 F1 · price: The common stock and warrants were acquired in a public offering, by Onconova Therapeutics, Inc, of units which included one share of common stock and one warrant. The public offering price for each unit was $0.20. Read SEC document |
| November 25, 2019 Filed Nov 27, 2019 13:33 UTC |
MEHTA VIRENDirector
|
PurchaseCommon Stock | 250,000 | $0.20 | $50,000.00 |
DisclosureSEC source: 0001179110-19-012105 · edgar.xml · nonDerivative · entry 1 MEHTA VIREN · CIK 0001238969 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,857 F1 · price: The common stock and warrants were acquired in a public offering, by Onconova Therapeutics, Inc, of units which included one share of common stock and one warrant. The public offering price for each unit was $0.20. F2 · balance_after: Includes 190 shares held jointly with Dr. Mehta's spouse. Read SEC document |
| September 25, 2019 Filed Sep 26, 2019 22:22 UTC |
MARINO JAMES JDirector
|
PurchaseWarrant (right to purchase) · Derivative | 1,472.5 | Not disclosed Strike: $0.11 | Not disclosed |
DisclosureSEC source: 0001179110-19-010682 · edgar.xml · derivative · entry 5 MARINO JAMES J · CIK 0001198578 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,472.5 Underlying: Series B Convertible Preferred Stock · 1,472.5 shares Expires 2022-12-31 F6 · kind: In connection with a purchase of the Company's common stock on September 25, 2019 the terms of a warrant to purchase Series B preferred stock, previously purchased on May 1,2018, were amended as follows: (1) the exercise price of the warrant to purchase one share of common stock on an as-exercised and as-converted basis was reduced from $0.425 per 0.025 share of Series B Preferred Stock to $0.10667 per 0.025 share of Series B Preferred Stock which, on an as-converted basis, equals $1.60 per share of common stock, and (2) the expiration date of the warrant was extended to December 31, 2022. The price for amending Series B Preferred Stock Warrants was $0.125 per share (on an as-converted basis per share of common stock). F6 · price: In connection with a purchase of the Company's common stock on September 25, 2019 the terms of a warrant to purchase Series B preferred stock, previously purchased on May 1,2018, were amended as follows: (1) the exercise price of the warrant to purchase one share of common stock on an as-exercised and as-converted basis was reduced from $0.425 per 0.025 share of Series B Preferred Stock to $0.10667 per 0.025 share of Series B Preferred Stock which, on an as-converted basis, equals $1.60 per share of common stock, and (2) the expiration date of the warrant was extended to December 31, 2022. The price for amending Series B Preferred Stock Warrants was $0.125 per share (on an as-converted basis per share of common stock). Read SEC document |
| September 25, 2019 Filed Sep 26, 2019 22:22 UTC |
MARINO JAMES JDirector
|
OtherWarrant (right to purchase) · Derivative | 1,472.5 | Not disclosed Strike: $0.43 | Not disclosed |
DisclosureSEC source: 0001179110-19-010682 · edgar.xml · derivative · entry 4 MARINO JAMES J · CIK 0001198578 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Series B Convertible Preferred Stock · 1,472.5 shares Expires not disclosed F4 · derivative.exercise_price: These warrants were acquired in a public offering, by the Company, of units which included one share of common stock and one warrant. The public offering price for each unit was $0.425. F6 · kind: In connection with a purchase of the Company's common stock on September 25, 2019 the terms of a warrant to purchase Series B preferred stock, previously purchased on May 1,2018, were amended as follows: (1) the exercise price of the warrant to purchase one share of common stock on an as-exercised and as-converted basis was reduced from $0.425 per 0.025 share of Series B Preferred Stock to $0.10667 per 0.025 share of Series B Preferred Stock which, on an as-converted basis, equals $1.60 per share of common stock, and (2) the expiration date of the warrant was extended to December 31, 2022. The price for amending Series B Preferred Stock Warrants was $0.125 per share (on an as-converted basis per share of common stock). F6 · price: In connection with a purchase of the Company's common stock on September 25, 2019 the terms of a warrant to purchase Series B preferred stock, previously purchased on May 1,2018, were amended as follows: (1) the exercise price of the warrant to purchase one share of common stock on an as-exercised and as-converted basis was reduced from $0.425 per 0.025 share of Series B Preferred Stock to $0.10667 per 0.025 share of Series B Preferred Stock which, on an as-converted basis, equals $1.60 per share of common stock, and (2) the expiration date of the warrant was extended to December 31, 2022. The price for amending Series B Preferred Stock Warrants was $0.125 per share (on an as-converted basis per share of common stock). F5 · derivative.expiration_date: The warrants were exercisable immediately at an exercise price of $0.425 per 0.025 share of Series B Convertible Preferred Stock and would expire on the 18-month anniversary of the date on which the Company publicly announced through the filing of a Current Report on Form 8-K that a Charter Amendment, increasing the number of available common shares, has been filed with the Secretary of State of the State of Delaware. Read SEC document |
| September 25, 2019 Filed Sep 26, 2019 22:22 UTC |
MARINO JAMES JDirector
|
PurchaseWarrant (right to purchase) · Derivative | 5,000 | Not disclosed Strike: $0.11 | Not disclosed |
DisclosureSEC source: 0001179110-19-010682 · edgar.xml · derivative · entry 3 MARINO JAMES J · CIK 0001198578 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Series A Convertible Preferred Stock · 5,000 shares Expires 2022-12-31 F3 · kind: In connection with a purchase of the Company's common stock on September 25, 2019 the terms of a warrant to purchase Series A preferred stock, previously purchased on February 12, 2018, were amended as follows: (1) the exercise price of the warrant to purchase one share of common stock on an as-exercised and as-converted basis was reduced from $1.01 per 0.1 share of Series A Preferred Stock to $0.10667 per 0.1 share of Series A Preferred Stock which, on an as-converted basis, equals $1.60 per share of common stock, and (2) the expiration date of the warrant was extended to December 31, 2022. The price for amending Series A Preferred Stock Warrants was $0.125 per share (on an as-converted basis per share of common stock). F3 · price: In connection with a purchase of the Company's common stock on September 25, 2019 the terms of a warrant to purchase Series A preferred stock, previously purchased on February 12, 2018, were amended as follows: (1) the exercise price of the warrant to purchase one share of common stock on an as-exercised and as-converted basis was reduced from $1.01 per 0.1 share of Series A Preferred Stock to $0.10667 per 0.1 share of Series A Preferred Stock which, on an as-converted basis, equals $1.60 per share of common stock, and (2) the expiration date of the warrant was extended to December 31, 2022. The price for amending Series A Preferred Stock Warrants was $0.125 per share (on an as-converted basis per share of common stock). Read SEC document |
| September 25, 2019 Filed Sep 26, 2019 22:22 UTC |
MARINO JAMES JDirector
|
OtherWarrant (right to purchase) · Derivative | 5,000 | Not disclosed Strike: $1.01 | Not disclosed |
DisclosureSEC source: 0001179110-19-010682 · edgar.xml · derivative · entry 2 MARINO JAMES J · CIK 0001198578 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Series A Convertible Preferred Stock · 5,000 shares Expires not disclosed F1 · derivative.exercise_price: These warrants were acquired in a public offering, by Onconova Therapeutics, Inc. (the Company), of units which included one share of common stock and one warrant. The public offering price for each unit was $1.01. F3 · kind: In connection with a purchase of the Company's common stock on September 25, 2019 the terms of a warrant to purchase Series A preferred stock, previously purchased on February 12, 2018, were amended as follows: (1) the exercise price of the warrant to purchase one share of common stock on an as-exercised and as-converted basis was reduced from $1.01 per 0.1 share of Series A Preferred Stock to $0.10667 per 0.1 share of Series A Preferred Stock which, on an as-converted basis, equals $1.60 per share of common stock, and (2) the expiration date of the warrant was extended to December 31, 2022. The price for amending Series A Preferred Stock Warrants was $0.125 per share (on an as-converted basis per share of common stock). F3 · price: In connection with a purchase of the Company's common stock on September 25, 2019 the terms of a warrant to purchase Series A preferred stock, previously purchased on February 12, 2018, were amended as follows: (1) the exercise price of the warrant to purchase one share of common stock on an as-exercised and as-converted basis was reduced from $1.01 per 0.1 share of Series A Preferred Stock to $0.10667 per 0.1 share of Series A Preferred Stock which, on an as-converted basis, equals $1.60 per share of common stock, and (2) the expiration date of the warrant was extended to December 31, 2022. The price for amending Series A Preferred Stock Warrants was $0.125 per share (on an as-converted basis per share of common stock). F2 · derivative.expiration_date: The warrants were exercisable immediately at an exercise price of $1.01 per 0.1 share of Series A Convertible Preferred Stock and would expire on the later of (i) the one-year anniversary of the date on which theCompany publicly announces through the filing of a Current Report on Form 8-K that a Charter Amendment, increasing the number of available common shares, has been filed with the Secretary of State of the State of Delaware and (ii) the earlier of (A) the one-month anniversary of the date on which the Company publically releases certain topline results of the INSPIRE Pivotal phase 3 trial that compare the overall survival (OS) of patients in the rigosertib group vs the Physician's Choice group, in all patients and in a subgroup of patients with IPSS-R very high risk and (B) December 31, 2019. Read SEC document |
| September 25, 2019 Filed Sep 26, 2019 22:22 UTC |
MARINO JAMES JDirector
|
PurchaseCommon Stock | 7,260 | $1.60 | $11,616.00 |
DisclosureSEC source: 0001179110-19-010682 · edgar.xml · nonDerivative · entry 1 MARINO JAMES J · CIK 0001198578 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,942 Read SEC document |
| September 24, 2019 Filed Sep 26, 2019 20:16 UTC |
TYNDALL CAPITAL PARTNERS L P10% owner
|
SaleCommon Stock | 16,700 | $1.19 | $19,873.00 |
DisclosureSEC source: 0000905718-19-000789 · onconova_fm4sept242019.xml · nonDerivative · entry 1 TYNDALL CAPITAL PARTNERS L P · CIK 0001219314 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Note Disclosed balance after: 616,389 F1 · ownership.nature: Tyndall Capital Partners, L.P. ("Tyndall Capital") is the general partner of Tyndall Partners, L.P. ("Tyndall"), and possesses the sole power to vote and the sole power to direct the disposition of all securities held by Tyndall. Tyndall Capital's interest in the securities reported herein is limited to the extent of its pecuniary interest in such securities, if any. Read SEC document |
| September 23, 2019 Filed Sep 24, 2019 20:08 UTC |
TYNDALL CAPITAL PARTNERS L P10% owner
|
SaleCommon Stock | 37,242 | $1.23 | $45,967.80 |
DisclosureSEC source: 0000905718-19-000785 · onconova_fm4sept202019.xml · nonDerivative · entry 2 TYNDALL CAPITAL PARTNERS L P · CIK 0001219314 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Note Disclosed balance after: 633,089 F1 · ownership.nature: Tyndall Capital Partners, L.P. ("Tyndall Capital") is the general partner of Tyndall Partners, L.P. ("Tyndall"), and possesses the sole power to vote and the sole power to direct the disposition of all securities held by Tyndall. Tyndall Capital's interest in the securities reported herein is limited to the extent of its pecuniary interest in such securities, if any. Read SEC document |
| September 23, 2019 Filed Sep 25, 2019 21:41 UTC |
ARMISTICE CAPITAL, LLC10% owner
Armistice Capital Master Fund Ltd.10% owner
Boyd Steven10% owner
|
SaleCommon Stock | 0 | $0.00 | $0.00 |
DisclosureSEC source: 0000919574-19-006024 · ownership.xml · nonDerivative · entry 2 ARMISTICE CAPITAL, LLC · CIK 0001601086 · 10% owner Armistice Capital Master Fund Ltd. · CIK 0001633584 · 10% owner Boyd Steven · CIK 0001706140 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 816,702 F1 · ownership.nature: The reported securities are directly owned by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the "Master Fund"). The reported securities may be deemed to be indirectly beneficially owned by Armistice Capital, LLC, as the investment manager of the Master Fund. The reported securities may also be deemed to be indirectly beneficially owned by Steven Boyd as Managing Member of Armistice Capital, LLC. Armistice Capital, LLC and Steven Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interest therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.